The DIAGNODE- 1 trial showed promising efficacy (28) and in the DIAGNODE 2 study, with similar design,which we also use in the GAD-in LADA study, persons with recent onset type 1 diabetes and HLA haplotype DR3-DQ2 showed preservation of beta cell function after intra-lymphatic injections of GAD-alum (31). Here, GAD1 is linked to type 1 diabetes mellitus.